Indeed, the evaluation of an ER+ breast cancer cohort with a 10‐year follow‐up (Fig 6M, Table EV6), identified increased AHR, DDA1, and UBE4B levels in the primary tumors that relapsed (Figs 6O, EV4O and Q, Table EV7). Here, AHR is linked to breast carcinoma.